IFNA1 and viral infectious disease: We therefore suggest that targeting IFN to the liver for the treatment of hepatropic virus infections such as HCV may result in increased efficacy through delivering the dose to the site of action but also that the dose of IFN could be reduced and the level of efficacy would be similar to the current standard of care.